Navegar por los elementos (841 total)

• An integrative review of the limited evidence on international travel bans as an emerging infectious disease disaster control measure.

  Etiquetas Ebola, Infection Prevention and Control, MERS-CoV, R-Res&Pub, SARS, Special Pathogens
  Autor: Errett, Nicole A., Lauren M. Sauer, and Lainie Rutkow.
  Tema: Research
  Tipo de elemento: Publicación
  Fecha de actualización: 2020-02
  Descripción: In our increasingly interconnected world, the potential for emerging infectious diseases (EIDs) to spread globally is of paramount concern.
• 

  Rapid risk assessment: Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV), 22nd update

  Etiquetas MERS-CoV, R-T&C, Respiratory Pathogen, Zoonotic
  Autor: European Union, European Centre for Disease Prevention and Control (ECDC)
  Tema: Infection Control
  Tipo de elemento: Guía
  Fecha de actualización: 2018-08-29
  Descripción: This update of ECDC’s risk assessment on MERS-CoV was triggered by the detection of a case imported into the EU/EEA from the Kingdom of Saudi Arabia (KSA). In this update, we reassess the risk for EU/EEA residents.
• 

  Ebola or Not? Evaluating the Ill Traveler From Ebola-Affected Countries in West Africa.

  Etiquetas Diagnosis, Ebola, Person Under Investigation (PUI), R-IIT, R-Lead, R-Res&Pub, Special Pathogens
  Autor: Fairley, J. K., P. E. Kozarsky, C. S. Kraft, J. Guarner, J. P. Steinberg, E. Anderson, J. T. Jacob, P. Meloy, D. Gillespie, T. R. Espinoza, A. Isakov, S. Vanairsdale, E. Baker and H. M. Wu
  Tema: Intake and Internal Transport
  Tipo de elemento: Publicación
  Fecha de actualización: 2016-01-18
  Descripción: The 2014-2015 Ebola epidemic in West Africa had global impact beyond the primarily affected countries of Guinea, Liberia, and Sierra Leone. 

• Ebola therapies: an unconventionally calculated risk.

  Etiquetas Clinical Trial, Ebola, Outbreaks, R-Res&Pub, Therapeutics, Vaccine Study
  Autor: Fallah MP, Skrip LA.
  Tema: Research
  Tipo de elemento: Publicación
  Fecha de actualización: 2019-01-24
  Descripción: This article reviews the testing of Ebola therapies during the outbreak.

• Literature Review: Room Ventilation and Airborne Disease Transmission

  Etiquetas Airborne Transmission, Engineering Controls, Example, Physical Infrastructure, R-Lead, R-PhIn
  Autor: Farhad Memarzadeh, ASHE-FGI monograph
  Tema: Physical Infrastructure
  Tipo de elemento: Publicación
  Fecha de actualización: 2013
  Descripción: Current recommended ventilation rates for health care facilities are not always based on hard data, but on experience. In this joint ASHE-FGI monograph, Farhad Memarzadeh, PhD, PE, looks at research on hospitals, schools, aircraft, and other vehicles…

  Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.

• Vaccine innovation spurred by the long wait for an Ebola virus vaccine

  Etiquetas Ebola, Example, R-Lab, R-Res&Pub, Vaccine Study, Viral Hemorrhagic Fever
  Autor: Fausther-Bovendo, Hugues, and Gary Kobinger.
  Tema: Laboratory
  Tipo de elemento: Publicación
  Fecha de actualización: 2020-11-17
  Descripción: The 2013–16 Ebola virus outbreak—the largest ever recorded—substantially hastened the development of an Ebola virus vaccine. Before this outbreak, the safety and immunogenicity of only two Ebola virus vaccine candidates (a DNA-based vaccine and a…

  Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.

• Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1)

  Etiquetas Institutional Review Board (IRB), NSPS 1, NSPS 2, R-Res&Pub, Research, Research Design
  Autor: FDA
  Tema: Research
  Tipo de elemento: Hipervínculo
  Fecha de actualización: 2021-05
  Descripción: Guidance for Sponsors, Clinical Investigators, and IRBs. Information for investigational new drugs (IND).
  Draft Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA…
• 

  JYNNEOS Dosage Information

  Etiquetas Mpox, R-T&C, Smallpox, Treatment and Care, Vaccine Study
  Autor: FDA
  Tema: Treatment & Care
  Tipo de elemento: Guía
  Fecha de actualización: 2022-04
  Descripción: JYNNEOS is a vaccine indicated for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.Includes: indications and usage, dosage and administration, dosage…

• Investigational New Drug (IND) Application

  Etiquetas NSPS 1, NSPS 2, R-Res&Pub, Research, Therapeutics
  Autor: FDA
  Tema: Research
  Tipo de elemento: Hipervínculo
  Fecha de actualización: 2022-07-20
  Descripción: Current Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will probably want to ship the investigational drug to clinical investigators…

• Emergency Use Authorization

  Etiquetas Emergency Management, R-Res&Pub, Research, Therapeutics
  Autor: FDA
  Tema: Research
  Tipo de elemento: Hipervínculo
  Fecha de actualización: 2023-05-12
  Descripción: The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against chemical, biological, radiological, and nuclear (CBRN) threats including infectious diseases, by facilitating the…